DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCorporate Action

Alkem Laboratories Limited — Appointment

NSE 1 hr ago·3 Nov 2026, 8:04 am

Alkem Laboratories

Alkem Laboratories has announced the appointment of Dr. Amrut Naik as its new Chief Executive Officer (CEO), effective November 11, 2026. He will also serve as a Key Managerial Personnel for the company. This move comes as the current leadership prepares for a transition period, with Dr. Naik stepping into the top role to guide the firm's future strategy.

This appointment is significant for investors as it signals a planned leadership change to ensure business continuity and strategic direction. Dr. Naik's role will be crucial in steering Alkem's operations and growth initiatives. Market participants will be keen to observe his strategic vision and how it aligns with the company's long-term goals once he assumes the position.